Universität zu Köln

Hallek, Michael, Shanafelt, Tait D. and Eichhorst, Barbara (2018). Chronic lymphocytic leukaemia. Lancet, 391 (10129). S. 1524 - 1538. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-547X

Full text not available from this repository.

Abstract

Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Shanafelt, Tait D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichhorst, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-189328
DOI:	10.1016/S0140-6736(18)30422-7
Journal or Publication Title:	Lancet
Volume:	391
Number:	10129
Page Range:	S. 1524 - 1538
Date:	2018
Publisher:	ELSEVIER SCIENCE INC
Place of Publication:	NEW YORK
ISSN:	1474-547X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PREVIOUSLY UNTREATED PATIENTS; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; PROGRESSION-FREE SURVIVAL; PHASE-II TRIAL; BIWEEKLY CHLORAMBUCIL TREATMENT; INTERNATIONAL PROGNOSTIC INDEX; STEM-CELL TRANSPLANTATION; SERUM THYMIDINE KINASE; OPEN-LABEL; HIGH-RISK Multiple languages Medicine, General & Internal Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/18932